NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
June 11, 2024 06:00 ET
|
NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel...
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
June 11, 2024 01:00 ET
|
NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing...
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
March 21, 2024 07:00 ET
|
NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
March 21, 2024 02:00 ET
|
NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences
March 01, 2024 14:00 ET
|
NMD Pharma
NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences ClC-1 is a chloride ion channel specifically expressed...
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society
October 03, 2023 07:00 ET
|
NMD Pharma
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society NMD Pharma will show the first ever...
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society
October 03, 2023 01:00 ET
|
NMD Pharma
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society NMD Pharma will show the first ever...
NMD Pharma to host a Satellite Symposium* and present new clinical data at the 148th Annual Meeting of the American Neurological Association
September 08, 2023 07:00 ET
|
NMD Pharma
NMD Pharma to host a Satellite Symposium* and present new clinical data at the 148th Annual Meeting of the American Neurological Association NMD Pharma to host a satellite symposium* at the...
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2
June 20, 2023 07:00 ET
|
NMD Pharma
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Results from the study establish, for the...
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2
June 20, 2023 01:00 ET
|
NMD Pharma
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Results from the study establish, for the...